What is Lucence?
Founded in 2016 and headquartered in Singapore, Lucence is at the forefront of precision oncology. The company specializes in the development of advanced liquid biopsy blood tests. These tests are designed to perform molecular profiling, enabling the selection of the most effective cancer treatments for patients. Lucence's innovative approach aims to revolutionize cancer care by providing personalized therapeutic strategies through non-invasive blood analysis.
How much funding has Lucence raised?
Lucence has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2019): $20M with participation from Lim Kaling, IHH Healthcare, Heliconia Capital, Koh Boon Hwee, and SGInnovate
Key Investors in Lucence
SGInnovate
SGInnovate is dedicated to growing Singapore's Deep Tech landscape by investing in startups and nurturing talent within the sector. They provide resources and support for Deep Tech companies, facilitating career development and job opportunities.
What's next for Lucence?
The recent major strategic investment signifies a pivotal moment for Lucence, likely enabling the company to accelerate its research and development efforts, expand its clinical validation studies, and scale its commercial operations. This enterprise-level funding suggests a strong market appetite for Lucence's precision oncology solutions, positioning the company for significant growth and impact in the global fight against cancer. Future endeavors will likely focus on broadening the application of their liquid biopsy technology and forging strategic partnerships within the healthcare ecosystem.
See full Lucence company page
